3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Uterine Cervical Neoplasms
2
Advanced Solid Tumours
2
Vaginal Neoplasms
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Previously Treated Non Small Cell Lung Cancer
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Endometrioid
1
Blast Crisis
1
Advanced Solid Tumors
1
Interventions
Gemcitabine
34
pembrolizumab
26
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
adavosertib
×
Clear all
NCT02576444
2022-12-28
OLAPCO
Yale University
Phase 2
Terminated
67 enrolled
10 charts